Irreversible corneal decompensation in patients treated with topical dorzolamide

American Journal of Ophthalmology

Volumn 127, Issue 4, 1999, Pages 403-406

  Konowal, A ^a   Morrison, J C ^c   Brown, S V L ^a   Cooke, D L ^a   Maguire, L J ^b   Verdier, D V ^b   Fraunfelder, F T ^c   Dennis, R F ^a   Epstein, R J ^a  

^a RUSH UNIVERSITY MEDICAL CENTER   (United States)

^b MAYO CLINIC   (United States)

^c OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DORZOLAMIDE;

ADULT; AGED; ARTICLE; CHRONOTHERAPY; CLINICAL ARTICLE; CORNEA EDEMA; CORNEA EPITHELIUM; CORNEA SURGERY; DISEASE SEVERITY; DOSE TIME EFFECT RELATION; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; GLAUCOMA; GRAFT REJECTION; HUMAN; MALE; PENETRATING KERATOPLASTY; PRIORITY JOURNAL; TOPICAL DRUG ADMINISTRATION; TREATMENT OUTCOME;

ADMINISTRATION, TOPICAL; ADULT; AGED; AGED, 80 AND OVER; CARBONIC ANHYDRASE INHIBITORS; CORNEAL EDEMA; ENDOTHELIUM, CORNEAL; FEMALE; GLAUCOMA; HUMANS; INTRAOCULAR PRESSURE; KERATOPLASTY, PENETRATING; MALE; MIDDLE AGED; OPHTHALMIC SOLUTIONS; REFRACTIVE ERRORS; RETROSPECTIVE STUDIES; SULFONAMIDES; THIOPHENES; VISUAL ACUITY;

EID: 0033119461     PISSN: 00029394     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9394(98)00438-3     Document Type: Article

References (25)

1. Friedland B.R., Maren T.H. Carbonic anhydrase inhibitors. Ritch R., Shields M.B., Krupin T. The glaucomas. 1989;539-549 CV Mosby, St Louis.
2. Pfeiffer N. Dorzolamide: development and clinical application of a topical carbonic anhydrase inhibitor. Surv Ophthalmol 1997;42;2:137-151.
3. Wang R.F., Serle J.B., Podos S.M., Sugrue M.F. MK-507(L-671,152), a topically active carbonic anhydrase inhibitor, reduces aqueous humor production in monkeys. Arch Ophthalmol. 109:1991;1297-1299.
4. Lippa E.A., Schuman J.S., Higginbotham E.J., et al. MK-507 versus sezolamide comparative efficacy of two topically active carbonic anhydrase inhibitors . Ophthalmol. 98:1991;308-312.
5. Wilkerson M., Cyrlin M., Lippa E.A., et al. Four week safety and efficacy study of dorzolamide, a novel, active topical carbonic anhydrase inhibitor. Arch Ophthalmol. 111:1993;1343-1350.
6. Lippa E.A., Carlson L.E., Ehinger B., et al. Dose response and duration of action of dorzolamide, a topical carbonic anhydrase inhibitor. Arch Ophthalmol. 110:1992;495-499.
7. Kass M.A., Laibovitz R.A., Lippa E.A., et al. Comparative activity of 3% MK-507, a topical CAI, with betaxolol. [abstract] Invest Ophthalmol Vis Sci. 32:(suppl):1991;989.
8. Strahlman E.R., Deasy D., Panebianco D. A 2-week pilot activity study of a fixed combination of timolol and dorzolamide hydrochloride. [abstract] Invest Ophthalmol Vis Sci. 34:(suppl):1993;1148.
9. Merck Research Laboratories Clinical Study Report (Synopsis) Multicenter study. A single-dose, randomized, double-masked, six-period crossover, ocular tolerability comparison study of L-671,152 (MK-507) and MK-417 ophthalmic solutions in healthy volunteers. West Point, Pennsylvania: Merck and Co, Inc, 1992: Protocol 007.
10. Lippa E.A., Clineschmidt C.M., Tipping R.W., Strohmaier K.M. Dorzolamide Dose-Response Study Group. Dorzolamide hydrochloride: 6 week, dose-response study of an active topical carbonic anhydrase inhibitor. [abstract] Invest Ophthalmol Vis Sci. 34:(suppl):1993;1149.
11. A topical carbonic anhydrase inhibitor for glaucoma. Med Lett. 37:(956):1995;76-77.
12. Hull D.S., Green K., Boyd M., Wynn H.R. Corneal endothelium bicarbonate transport and the effect of carbonic anhydrase inhibitors on endothelial permeability and fluxes and corneal thickness. Invest Ophthalmol Vis Sci. 16:1977;883-892.
13. Sharir M., Pierce W.M. Jr, Ochsner K.I., Eiferman R.A. Novel topical thiadiazoles and benzothiazoles as pharmacological probes of corneal endothelial function. J Ocul Pharmacol. 9:1993;333-340.
14. Serle J.B., Podos S.M., Lippa E.A., et al. Compassionate case usage of dorzolamide (MK-507) in 16 glaucoma patients. Invest Ophthalmol Vis Sci. 35:(suppl):1994;2177.
15. Kitazawa Y., Azuma I., Araie M., et al. Topical dorzolamide hydrochloride can be a substitute for oral carbonic anhydrase inhibitors. Invest Ophthalmol Vis Sci. 35:(suppl):1994;2177.
16. Bazard M.C., Tankosic P., Kohler F., Berrod J.P., Raspiller A. Endothelial morphometry and perforating keratoplasties. J Fr Ophthalmol. 11:1988;261-268.
17. Bourne W.M., Hodge D.O., Nelson L.R. Corneal endothelium five years after transplantation. Am J Ophthalmol. 118:1994;185-196.
18. Matsuda M., Bourne W.M. Long-term morphologic changes in the endothelium of transplanted corneas. Arch Ophthalmol. 103:(9):1985;1343-1346.
19. Musch D.C., Schwartz A.E., Fitzgerald-Shelton K., Sugar A., Meyer R.F. The effect of allograft rejection after penetrating keratoplasty on central endothelial cell density. Am J Ophthalmol. 111:1991;739-742.
20. Faulkner G.D. Endothelial cell loss after phacoemulsification and insertion of silicone lens implants. J Cataract Refract Surg. 13:1987;649-652.
21. Werblin T.P. Long-term endothelial cell loss following phacoemulsification model for evaluating endothelial damage after intraocular surgery . Refract Corneal Surg. 9:1993;29-35.
22. Kreisler K.R., Mortenson S.W., Mamalis N. Endothelial cell loss following "modern" phacoemulsification" by a senior resident. Ophthalmic Surg. 23:1992;158-160.
23. Rosenberg L.F., Krupin T., Tang L.Q., Hong P.H., Ruderman J.M. Combination of systemic dorzolamide in reducing intraocular pressure and aqueous humor formation. Ophthalmology. 105:1998;88-93.
24. Egan C.A., Hodge D.O., McLaren J.W., et al. Effect of dorzolamide on corneal endothelial function in normal human eyes. Invest Ophthalmol Vis Sci. 39:1998;23-29.
25. Lass J.A., Khosrof S.A., Laurence J.K., et al. A double-masked, randomized, 1-year study comparing the corneal effects of dorzolamide, timolol, and betaxolol. Arch Ophthalmol. 116:1998;1003-1010.